Anavar (Oxandrolone): Clinical Uses, Dosing, Side Effects, and How It Compares to SARMs

What Is Oxandrolone and Why Was It Developed?

Oxandrolone is a synthetic derivative of testosterone, modified at the 2-position of the A-ring and at the 17-alpha position to survive first-pass hepatic metabolism. Searle Laboratories introduced it in 1964 under the brand name Anavar, specifically designed to produce anabolic effects with reduced androgenicity. The FDA granted approval for short-term weight restoration after involuntary weight loss, adjunctive treatment of osteoporosis, and relief of bone pain. It remains one of the few oral anabolic steroids with an active FDA-approved labeling.

The 2-oxa modification lowers the compound's affinity for 5-alpha reductase, which means it converts to dihydrotestosterone (DHT) at a much lower rate than testosterone. That single structural change accounts for much of its comparatively mild virilization profile, making it the most commonly prescribed oral anabolic steroid for women and children in clinical settings. The 17-alpha alkylation, however, is the chemical feature responsible for hepatotoxicity risk, a trade-off shared by all oral 17-alpha alkylated androgens.

Oxandrolone binds the androgen receptor (AR) at approximately 4, 6 times the affinity of testosterone. Studies using radiolabeled competitive binding assays have confirmed this affinity advantage, which partly explains why clinically effective doses are small in absolute milligram terms compared to testosterone esters.

FDA-Approved Indications and Off-Label Clinical Uses

The FDA label covers three specific situations: short-term weight gain in patients who have lost weight due to surgery, chronic infection, or severe trauma; adjunctive therapy to promote bone density in osteoporosis; and relief of bone pain associated with osteoporosis. These are not marketing categories. They reflect decades of controlled clinical experience.

Off-label uses that have been studied in peer-reviewed literature include:

Burn injury recovery. A randomized controlled trial by Jeschke et al. published in Annals of Surgery enrolled 334 pediatric burn patients. Children receiving oxandrolone 0.1 mg/kg twice daily had a mean hospital length of stay that was 26 days shorter than placebo controls, alongside statistically significant improvements in lean body mass and bone mineral content at 12 months post-injury. Read the trial.

HIV-associated wasting. A 2004 randomized trial published by Strawford et al. demonstrated that oxandrolone 20 mg/day combined with progressive resistance training produced significantly greater gains in lean body mass compared to exercise alone in men with HIV-associated weight loss. Source.

Short stature / Turner syndrome. The FDA label includes pediatric growth promotion. The 2023 Endocrine Society Clinical Practice Guideline on Growth Hormone Deficiency notes oxandrolone as an adjunct option in girls with Turner syndrome when growth velocity remains insufficient on GH alone.

Alcoholic hepatitis. A Cochrane review of 15 RCTs found no mortality benefit for androgenic steroids including oxandrolone in alcoholic hepatitis, though some trials showed short-term improvements in nutritional markers. Oxandrolone is not recommended for this indication by current hepatology guidelines. Cochrane review.

Dosing Protocols by Clinical Context

Dosing oxandrolone correctly depends on the clinical goal, the patient's sex, body weight, and the duration planned. The FDA-labeled dose for adults is 2.5 to 20 mg/day given in 2, 4 divided doses, taken with food, for periods of 2 to 4 weeks with possible repeat courses after a rest interval.

Men. In weight-restoration protocols, 10 to 20 mg/day is the most commonly studied range. Burn literature uses weight-based dosing of 0.1 mg/kg twice daily. Doses above 20 mg/day used beyond 8 weeks substantially increase the risk of suppression of the hypothalamic-pituitary-gonadal (HPG) axis and hepatic enzyme elevation.

Women. The standard clinical range is 2.5 to 10 mg/day. Virilizing side effects, including clitoral enlargement, voice deepening, and facial hair growth, become dose-dependent above 10 mg/day and may be irreversible with prolonged exposure. The 2.5 to 5 mg/day range is commonly used in oncology-related wasting and post-surgical recovery in women, with a favorable benefit-to-risk ratio when courses stay under 12 weeks.

Children. Pediatric dosing is strictly weight-based (0.05 to 0.1 mg/kg/day). Premature closure of epiphyseal plates is a concern in prepubertal patients; bone age radiographs every 6 months are standard practice. This application should only occur under specialist endocrine supervision.

Oral administration with food reduces gastrointestinal discomfort. The approximately 9 to 10 hour half-life supports twice-daily dosing to maintain steadier plasma concentrations compared to once-daily regimens.

Mechanism of Action: Full AR Agonism vs. SARM Partial Agonism

Understanding why oxandrolone differs from SARMs requires a brief look at receptor pharmacology. Oxandrolone is a full agonist at the androgen receptor. Once bound, it recruits coactivator proteins, triggers genomic transcription, and produces downstream anabolic effects in muscle, bone, and connective tissue across multiple tissues simultaneously.

SARMs (selective androgen receptor modulators) are designed to be tissue-selective partial agonists. The underlying concept is sound: if a compound fully activates AR in muscle and bone while only partially activating it in the prostate and sebaceous glands, you could achieve anabolic benefits with fewer androgenic side effects. In practice, selectivity in preclinical rodent models has not translated cleanly to humans. No SARM has completed FDA approval for any indication.

Ostarine (MK-2866). Phase II trials in cancer patients showed modest lean mass gains at 3 mg/day over 16 weeks. A published Phase II RCT (N=159) showed 1.4 kg lean mass gain vs. 0.5 kg placebo (P<0.001), but no Phase III trial has succeeded in gaining FDA approval. The FDA issued a warning in 2017 that SARMs are unapproved new drugs and may not be marketed as dietary supplements. FDA warning letter.

Ligandrol (LGD-4033). A Phase I trial (N=76 healthy men) showed dose-dependent lean mass increases of 1.21 kg at 1 mg/day over 21 days with dose-dependent testosterone suppression. Published by Basaria et al. in Journals of Gerontology. No approved indication exists. Several competitive athletes have received multi-year bans after LGD-4033 appeared in doping tests.

RAD-140 (Testolone). RAD-140 is in Phase I trials for breast cancer and has the highest anabolic-to-androgenic ratio among commonly discussed SARMs in animal data. Human safety data beyond small Phase I cohorts is not publicly available. Two published case reports document acute drug-induced liver injury (DILI) attributed to RAD-140 supplementation. One case report in ACG Case Reports Journal.

Cardarine (GW-501516). Cardarine is not technically a SARM. It is a PPARdelta agonist. It is frequently grouped with SARMs in the bodybuilding community, but its mechanism is entirely different. GlaxoSmithKline discontinued development of GW-501516 in 2007 after animal carcinogenicity studies showed rapid tumor development in multiple organ systems at doses used in rodent models. NIH toxicology reference. No human efficacy or safety trials have been completed. Cardarine is among the most pharmacologically concerning compounds commonly discussed in body-composition contexts.

The table below provides a structured comparison of oxandrolone vs. the four SARMs most commonly queried alongside it. This framework was developed by the HealthRX clinical team to standardize how providers communicate regulatory and safety distinctions to patients.

| Compound | Mechanism | FDA Status | Human RCT Data | Primary Safety Signal | |---|---|---|---|---| | Oxandrolone | Full AR agonist | Approved (Schedule III) | Extensive (60+ years) | Hepatotoxicity, HPG suppression, virilization | | Ostarine MK-2866 | Partial AR agonist | Not approved | Phase I/II only | HPG suppression, DILI (case reports) | | Ligandrol LGD-4033 | Partial AR agonist | Not approved | Phase I only | HPG suppression, lipid changes | | RAD-140 | Partial AR agonist | Phase I trials | Very limited | DILI (case reports), unknown long-term | | Cardarine GW-501516 | PPARdelta agonist | Discontinued | None (humans) | Carcinogenicity (animal data) |

Side Effects and Safety Profile

Oxandrolone's side effect profile is better characterized than that of any SARM because of its long clinical history. That does not mean the risk is trivial.

Hepatotoxicity. As a 17-alpha alkylated compound, oxandrolone stresses hepatic metabolism. Transient elevations of ALT and AST are common at doses above 10 mg/day and in courses longer than 8 weeks. Peliosis hepatis (blood-filled hepatic cysts) and cholestatic jaundice have been reported, primarily at doses used recreationally rather than medically, and usually with concurrent alcohol use or other hepatotoxins. Baseline and periodic liver function tests every 6 to 8 weeks are standard in any supervised protocol. Hepatotoxicity review in LiverTox.

HPG axis suppression. Exogenous androgens suppress LH and FSH through negative feedback at the hypothalamus and pituitary. In men, this reduces endogenous testosterone production and testicular volume. At 20 mg/day for 12 weeks, suppression of LH by 50 to 70% has been documented. For most men in medically supervised short courses, recovery of endogenous testosterone production occurs within 4 to 12 weeks post-cessation, but longer courses and higher doses extend recovery time.

Lipid effects. Oxandrolone, like other oral androgens, reduces HDL cholesterol. A mean HDL reduction of 20 to 30% has been observed at 20 mg/day in 12-week studies. LDL may increase modestly. Cardiovascular risk monitoring, including a fasting lipid panel at baseline and at 6 to 8 weeks into a course, is medically appropriate. Lipid effects review.

Virilization in women. The features of virilization (clitoral enlargement, voice changes, hirsutism) are dose- and duration-dependent. At 5 mg/day for 8 weeks, virilization rates in published trials have been low, under 5%. Voice changes, once established, may not fully reverse after stopping the drug.

Pediatric bone age acceleration. In prepubertal patients, oxandrolone advances bone age faster than chronological age, with potential for reduced final adult height if not carefully monitored. Bone age X-rays every 6 months are mandatory in pediatric protocols.

Mood and behavior. The androgenic and anabolic potency of oxandrolone is substantially lower than that of testosterone in terms of direct CNS effects, but irritability and mood changes have been reported in patients using doses above 20 mg/day, particularly in the context of other stressors.

Who Is a Candidate for Physician-Supervised Oxandrolone?

Medically appropriate candidates share a few common features: documented involuntary weight loss, impaired recovery from surgery or trauma, or a condition associated with lean mass depletion such as HIV wasting, severe burns, or cancer cachexia. The Endocrine Society's 2010 androgen therapy guidelines state: "We suggest against the use of androgens in healthy older men or women to improve body composition, physical performance, or sexual function." Endocrine Society guideline.

This means oxandrolone prescribed purely for aesthetic body-composition improvement in healthy individuals is off-label, not guideline-supported, and carries a Schedule III controlled substance legal framework. Patients with active hepatic disease, prostate cancer, breast cancer (in men), pregnancy, or nephrotic syndrome should not receive oxandrolone.

A thorough pre-treatment workup includes: CBC, CMP including liver enzymes, fasting lipid panel, PSA in men over 40, and a baseline testosterone level to assess HPG status before treatment begins.

Oxandrolone vs. Testosterone: When Does One Make More Sense?

Testosterone remains the first-line anabolic therapy for hypogonadal men. It is injectable, extensively studied, and its side effect profile is well understood across decades of TRT data. Oxandrolone does not convert to estradiol via aromatase, which means it does not cause gynecomastia through estrogenic mechanisms. For patients who are highly sensitive to estrogen-related effects or for women who need anabolic support without the systemic androgenicity of testosterone, oxandrolone may be a more practical option.

In post-surgical or burn contexts, oral dosing is often preferred over injectable testosterone because of ease of administration during recovery and the ability to titrate dose without the pharmacokinetic inertia of long-acting testosterone esters. A burn unit protocol using twice-daily oral oxandrolone is logistically simpler than weekly IM injections.

For men with primary hypogonadism needing long-term androgen replacement, testosterone (cypionate, enanthate, or transdermal) remains the standard of care. Oxandrolone is not a substitute for testosterone replacement in hypogonadism because it does not reliably maintain serum testosterone levels and will suppress endogenous production.

Regulatory and Legal Status

Oxandrolone has been a Schedule III controlled substance in the United States since the Anabolic Steroids Control Act of 1990. Legitimate prescriptions require a licensed prescriber, a valid patient-provider relationship, and documentation of a medical indication. Compounding pharmacies can prepare oxandrolone under a physician's prescription, which is how most telehealth providers accessing it for patients will encounter it.

WADA prohibits oxandrolone in all competitive sports at all times, both in and out of competition. Athletes subject to anti-doping rules should be aware that oxandrolone's urinary metabolites (notably 16-beta-hydroxylation products) are detectable for 3 to 4 weeks post-cessation with standard immunoassay screens, and significantly longer with IRMS (isotope ratio mass spectrometry) confirmatory testing.

The four SARMs discussed above are not Schedule III substances in the United States, but the FDA has clearly stated they are unapproved new drugs and cannot be legally sold as dietary supplements. The SARMs Control Act, introduced in both the 116th and 117th Congresses, would classify SARMs as Schedule III if passed, though as of this writing it has not been enacted into law. The legal gray area does not indicate safety.

Monitoring During a Supervised Oxandrolone Course

Responsible clinical management follows a simple cadence:

Before starting: Comprehensive metabolic panel (CMP) with liver function tests, CBC, fasting lipid panel, testosterone (total and free), PSA in men over 40, and weight with body composition if available.

At 4 to 6 weeks: Repeat liver enzymes (ALT, AST, total bilirubin), lipid panel, blood pressure check, and symptom review for virilization in women.

At 8 to 12 weeks (course end): Full metabolic panel, lipid panel, testosterone to assess HPG suppression, and patient-reported outcome measures for the original indication (weight, functional status, wound healing progress).

Post-course (4 to 8 weeks after stopping): Testosterone and gonadotropin levels to confirm HPG recovery in men. If LH and FSH remain suppressed beyond 12 weeks post-cessation, a supervised recovery protocol may be appropriate.

The American Association of Clinical Endocrinology (AACE) recommends that any anabolic-androgenic therapy be monitored with laboratory testing at intervals no greater than 3 months during active use.